ERBB2 and neoplasm: In addition, HER2-CAR-T can be combined with bispecific antibodies, such as bispecific antibodies Bi specific T-cell adaptor (BiTE), which can simultaneously bind to CD3 molecules on the surface of T cells and HER2 antigen molecules on the surface of tumor cells, thereby inducing T cells to kill tumor cells.